Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementA systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.FRAX®: prediction of major osteoporotic fractures in women from the general population: the OPUS study.UK clinical guideline for the prevention and treatment of osteoporosisAre glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?The risk of osteoporotic fractures according to the FRAX model in Korean patients with rheumatoid arthritis.Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fracturesA practical guide to the monitoring and management of the complications of systemic corticosteroid therapyAssociation between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional StudyHealth technology assessment in osteoporosis.Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos).Interpretation and use of FRAX in clinical practice.Corticosteroid-induced osteoporosis: an update for dermatologists.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.From fracture risk prediction to evaluating fracture patterns: recent advances in the epidemiology of osteoporosis.Management of glucocorticoid-induced osteoporosis.Type 2 diabetes and bone.Review of new guidelines for the management of glucocorticoid induced osteoporosis.The prevention of fragility fractures in diabetic patients.Reprint of: The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide.The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide.Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis.Prevention of glucocorticoid-induced fractures: which patients should we treat? Comment on the article by Grossman et al.Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX® algorithm useful?Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.Skeletal complications of rheumatoid arthritis.Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture.Glucocorticoids, Inflammation and Bone.Bone: Towards a better management of glucocorticoid-induced osteoporosis?Adjusting fracture probability by trabecular bone score.The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort studyAssessment of Fracture RiskTo FRAX or not to FRAX
P2860
Q24612411-CD5257EC-7581-4893-BD1E-944D99FDB207Q26998249-2F60BB20-E4E0-469D-B1ED-C25D13CFE3B0Q30248756-75AD856A-6452-4280-9D10-63046F736002Q30946308-46BCBE79-378F-4C1F-AA0F-0FAAE5ADEF70Q31147039-C5C50C1D-8FFF-451B-BF28-FAF27C295060Q33581078-13602FC4-EF8A-4A63-8BB2-62A1F3121F9DQ33912916-5A03757A-259A-4347-B5C3-B8AB4412C004Q34029944-AD75B4BE-3221-459D-B75D-71E013BE92FAQ34084507-541CE830-9DC6-4D37-8B72-832846647220Q34364143-C3D07CFE-D0B6-48AA-B7CF-CD6BC89F5C46Q35597615-BDCE45C1-C540-4EF1-B6F1-603B05F1F157Q36965411-77CD7023-4B3F-40B7-AFC1-631AC282A1F1Q37418453-5B4D0797-08E1-4DC5-861C-F4E80ADAE259Q37903748-7608371D-B097-4DF8-AE44-08D7FF784F32Q37990943-08D405F9-CE68-4577-9AAB-E4F98485D606Q37995500-6B68507D-70B9-4971-9617-F78D7A6792E6Q37997661-09A2AA4D-E4CA-4D7C-9CAB-924CDC4E3C71Q38033444-2E792CCE-B14D-4D1C-9D34-0AC5B9C3AE1DQ38048186-E27250A8-703B-4AAB-9EF2-7B7AEC496136Q38151513-393024E3-A428-4E87-BCDA-D58AFAB0F7D7Q38233593-5AD1C3BB-9764-4D7F-A74E-A40A68D85907Q38402233-483CF01A-5D85-4D18-876A-C849E3AED439Q38406462-775DD23A-9DB4-4977-8053-82144D907BDEQ38958696-80F4C796-5E13-4223-8C93-3ED28859C7FAQ45213278-5E403710-4B64-45AA-9428-F13180EAB7C7Q46527609-5D9ACF03-2AFA-4FCA-A894-FDE405D2616CQ46561872-6EEE0CAB-11F6-4BB4-BEA7-7FDBC26E1A71Q47117629-D9E1FB0F-82BE-4D7C-8C25-08A8836E4769Q47805955-3F4FDE43-134C-42D8-8152-CA1EFE03EE0EQ48139843-C3DB3212-F7D5-4BAA-8E4F-E05D784EEB30Q50128187-E5A14E3C-CACB-404C-9FA5-C7145B0BECEAQ50264358-5A76B818-A9E3-4C9F-A114-C69EDDA855CFQ50944575-8A1C2175-F4B7-45A5-A620-6C32BDE37107Q57416766-D3B5C8B6-8493-43D7-91C9-6093A77CE3A4Q57711517-FE90D70D-4CD5-4D6F-AAB8-2CD55B374F38Q58970550-994D2D92-2E1A-4EEB-846D-ACE546A52E9A
P2860
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@en
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@nl
type
label
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@en
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@nl
prefLabel
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@en
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@nl
P2093
P2860
P1476
Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
@en
P2093
E V McCloskey
H Johansson
P2860
P2888
P304
P356
10.1007/S00198-010-1524-7
P407
P577
2011-01-13T00:00:00Z
P6179
1050465667